Evolution of the Average Target: Charles River Laboratories International, Inc.

Evolution of the Target Price: Charles River Laboratories International, Inc.

Changes in Analyst Recommendations: Charles River Laboratories International, Inc.

33c3.YyBeOA_fpxuHVwwE8lawp_g8a_wbF22xrAEFH_LOeiI.FGYIaHu28SjVJEJXhhqJ8KxvWZ1xeyXf_2ZoTqemTWc6RTxJf6jfdf0bVQ~85cab5d39f91bd9615076d9a8e508fb3
09-25 Charles River Laboratories's DAS Segment Faces Largest Margin Upside, RBC Says MT
09-25 Deutsche Bank Raises Price Target on Charles River Laboratories International to $320 From $300, Keeps Buy Rating MT
09-25 RBC Raises Price Target on Charles River Laboratories International to $322 From $282, Keeps Outperform Rating MT
09-25 Evercore ISI Adjusts PT on Charles River Laboratories International to $330 From $320, Maintains Outperform Rating MT
09-25 Mizuho Adjusts PT on Charles River Laboratories International to $295 From $264, Keeps Neutral Rating MT
09-25 Barclays Adjusts PT on Charles River Laboratories International to $330 From $300, Keeps Overweight Rating MT
09-25 TD Cowen Adjusts PT on Charles River Laboratories International to $325 From $300, Maintains Buy Rating MT
09-25 Baird Adjusts PT on Charles River Laboratories International to $334 From $291, Keeps Outperform Rating MT
09-17 Argus Research Adjusts Charles River Laboratories International PT to $330 From $250, Maintains Buy Rating MT
09-11 Evercore ISI Adjusts PT on Charles River Laboratories International to $320 From $300, Maintains Outperform Rating MT
08-10 TD Cowen Adjusts PT on Charles River Laboratories International to $300 From $235, Maintains Buy Rating MT
08-10 Rothschild & Co Redburn Adjusts PT on Charles River Laboratories International to $318 From $241, Maintains Buy Rating MT
08-06 Barclays Adjusts Price Target on Charles River Laboratories International to $300 From $220 MT
08-06 RBC Adjusts PT on Charles River Laboratories International to $282 From $215, Keeps Outperform Rating MT
08-06 Deutsche Bank Adjusts Charles River Laboratories International PT to $300 From $260, Maintains Buy Rating MT
08-06 Analyst recommendations: AppLovin, Emerson Electric, Roblox, Flutter Entertainment, HubSpot... Zonebourse
08-06 JPMorgan Upgrades Charles River Laboratories International to Overweight From Neutral, Adjusts PT to $310 From $180 MT
07-20 Analyst recommendations: Global Payments, Charles Schwab, US Bancorp, Datadog, Netflix… Zonebourse
07-13 BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220 MT
07-13 Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating MT
07-13 Mizuho Adjusts Price Target on Charles River Laboratories International to $230 From $192, Maintains Neutral Rating MT
07-09 Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $260 From $220 MT
07-07 Evercore ISI Adjusts Price Target on Charles River Laboratories International to $260 From $220 MT
07-01 Argus Raises Price Target on Charles River Laboratories International to $250 From $200, Maintains Buy Rating MT
06-18 Rothschild & Co Redburn Adjusts Charles River Laboratories International PT to $241 From $230, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+2.03%
+20.9%
+2.8%
+23.88%
+19.94%
+50.95%
-5.99%
-19.36%
-6.61%
+38.36%
Average +12.69%
Weighted average by Cap. +16.24%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
292.84USD
Average target price
298.79USD
Spread / Average Target
+2.03%
High Price Target
334.00USD
Spread / Highest target
+14.06%
Low Price Target
145.00USD
Spread / Lowest Target
-50.48%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
AA
  1. Stock Market
  2. Stocks
  3. CRL Stock
  4. Consensus Charles River Laboratories International, Inc.